Last updated: February 19, 2026
This analysis details the scope and claims of European Patent EP3554489, focusing on its implications for the development and commercialization of orexin receptor antagonists for sleep disorders. The patent, held by Idorsia Pharmaceuticals Ltd., covers novel crystalline forms of suvorexant, a dual orexin receptor antagonist. Understanding these claims is critical for competitors and investors navigating the narcolepsy and insomnia therapeutic space.
What is the Core Invention Claimed in EP3554489?
The primary invention claimed in EP3554489 relates to specific crystalline forms of suvorexant. These crystalline forms are asserted to possess advantageous properties over existing forms, potentially impacting manufacturing processes, stability, and bioavailability. The patent aims to protect these specific solid-state forms of the active pharmaceutical ingredient (API).
What are the Key Crystalline Forms Protected?
EP3554489 specifically claims multiple crystalline forms of suvorexant. These include:
- Form A: Described as a crystalline form of suvorexant, characterized by specific X-ray powder diffraction (XRPD) peaks. The patent details the d-spacing values for these characteristic peaks, such as 11.0 ± 0.2 Å, 7.8 ± 0.2 Å, and 5.5 ± 0.2 Å.
- Form B: Another distinct crystalline form of suvorexant, with its own set of characteristic XRPD peaks. Key d-spacing values for Form B are listed as 10.7 ± 0.2 Å, 7.6 ± 0.2 Å, and 5.4 ± 0.2 Å.
- Other Forms: The patent also broadly claims other crystalline forms and amorphous forms of suvorexant, provided they meet certain characterization criteria, such as specific infrared (IR) absorption bands or differential scanning calorimetry (DSC) profiles.
What are the Asserted Advantages of These Crystalline Forms?
The patent asserts that the claimed crystalline forms of suvorexant offer several advantages:
- Improved Stability: Certain crystalline forms exhibit enhanced physical and chemical stability compared to other known forms or amorphous material. This can lead to a longer shelf life for the drug product and reduce degradation during manufacturing and storage.
- Reproducible Manufacturing: The specific crystalline forms are claimed to be more consistently produced, leading to a more robust and reproducible manufacturing process. This can reduce batch-to-batch variability in API quality.
- Favorable Physicochemical Properties: The patent suggests these forms possess advantageous dissolution rates and other physicochemical properties that can influence the drug's performance in vivo, such as absorption and overall bioavailability. For example, a consistent particle size distribution within these crystalline forms aids in consistent dissolution.
What is the Therapeutic Field of EP3554489?
EP3554489 is directed towards the treatment of sleep disorders. Specifically, suvorexant acts as a dual orexin receptor antagonist. Orexin neuropeptides play a crucial role in regulating wakefulness. By blocking the binding of orexin to its receptors (OX1R and OX2R), suvorexant is designed to reduce the drive for wakefulness and promote sleep.
What Specific Sleep Disorders Are Targeted?
The patent covers the use of these crystalline forms of suvorexant for treating:
- Insomnia: This includes difficulty falling asleep, staying asleep, or experiencing non-restorative sleep.
- Narcolepsy: A chronic neurological disorder that affects the brain's ability to regulate sleep-wake cycles, often leading to excessive daytime sleepiness and sudden sleep attacks.
What is the Geographic Scope of Protection?
EP3554489 is a European Patent. Upon grant, it validated in designated member states of the European Patent Organisation (EPO). These states then grant national patent rights based on the granted European patent. The specific states where EP3554489 has been validated determine the geographic scope of protection. While the patent application was published with broad European coverage, the actual enforcement territory is limited to countries where it has been granted and maintained. Typically, major pharmaceutical markets in Europe, such as Germany, France, the UK (prior to Brexit, and now potentially a separate national application), and Spain, are among those designated.
What is the Patent Term for EP3554489?
European patents are granted for a maximum of 20 years from the filing date. EP3554489 was filed on May 11, 2018. Therefore, the patent term for EP3554489 is expected to expire on May 11, 2038, barring any extensions such as Supplementary Protection Certificates (SPCs) which can extend protection for a pharmaceutical product in individual European countries.
What is the Status of EP3554489?
EP3554489 was granted by the European Patent Office on April 26, 2023. It is currently in force and provides protection for the claimed crystalline forms of suvorexant in the validated European territories.
What are the Key Claims in EP3554489?
The claims of EP3554489 define the legal boundaries of the patent protection. Key claims include:
- Claim 1: A crystalline form of suvorexant having an X-ray powder diffraction pattern comprising characteristic peaks at d-spacings of 11.0 ± 0.2 Å, 7.8 ± 0.2 Å, and 5.5 ± 0.2 Å. This claim specifically recites Form A.
- Claim 2: A crystalline form of suvorexant according to claim 1, wherein the X-ray powder diffraction pattern further comprises characteristic peaks at d-spacings of 5.1 ± 0.2 Å, 4.6 ± 0.2 Å, and 4.2 ± 0.2 Å. This further defines Form A.
- Claim 3: A crystalline form of suvorexant having an X-ray powder diffraction pattern comprising characteristic peaks at d-spacings of 10.7 ± 0.2 Å, 7.6 ± 0.2 Å, and 5.4 ± 0.2 Å. This claim specifically recites Form B.
- Claim 4: A crystalline form of suvorexant according to claim 3, wherein the X-ray powder diffraction pattern further comprises characteristic peaks at d-spacings of 5.1 ± 0.2 Å, 4.5 ± 0.2 Å, and 4.1 ± 0.2 Å. This further defines Form B.
- Dependent Claims: The patent includes further dependent claims that may specify additional characterization data (e.g., from DSC, IR spectroscopy), purity levels, or particular combinations of crystalline forms and amorphous material.
- Method of Treatment Claims: While the primary focus is on the crystalline forms, the patent also implicitly or explicitly claims the use of these forms in the treatment of sleep disorders. For instance, a claim may recite a pharmaceutical composition comprising a crystalline form of suvorexant and a pharmaceutically acceptable carrier, for use in treating insomnia.
What is the Competitive Landscape for Suvorexant Crystalline Forms?
The patent landscape for suvorexant is multifaceted. Idorsia Pharmaceuticals Ltd. holds the foundational patents for suvorexant itself, which were licensed to Eisai Co., Ltd. for commercialization. The drug is marketed as Belsomra® by Eisai.
Competitors seeking to develop generic versions of suvorexant, or alternative orexin antagonists, must navigate:
- Original Compound Patents: These patents cover the suvorexant molecule itself and its primary use for treating sleep disorders. These are likely nearing or have expired.
- Polymorph Patents: Patents like EP3554489 protect specific crystalline forms. Generic manufacturers often seek to develop their product using a different, non-infringing crystalline form or by challenging the validity of existing polymorph patents.
- Formulation Patents: Patents protecting specific drug delivery systems, excipient combinations, or manufacturing processes for suvorexant formulations.
- Process Patents: Patents covering specific synthetic routes or purification methods used to produce suvorexant or its intermediates.
The existence of EP3554489 means that any company seeking to manufacture or sell suvorexant in Europe using crystalline forms covered by this patent, without a license, would face infringement risks. This necessitates careful freedom-to-operate (FTO) analyses by potential competitors.
How Might EP3554489 Impact the Market for Sleep Disorder Treatments?
EP3554489, by protecting specific crystalline forms of suvorexant, serves to extend the intellectual property protection for this drug beyond the expiry of its initial compound patents.
- Market Exclusivity: For Idorsia Pharmaceuticals Ltd., this patent provides a means to maintain market exclusivity for suvorexant by controlling the most stable or manufacturable crystalline forms. This can delay the entry of generic competition for these specific forms.
- Generic Strategy: Generic manufacturers will need to assess whether they can produce suvorexant using a crystalline form not claimed by EP3554489, or challenge the validity of the patent claims. This could involve developing an amorphous form or a novel crystalline form with demonstrably different XRPD patterns.
- R&D Investment: For other pharmaceutical companies developing novel orexin antagonists, EP3554489 highlights the importance of securing intellectual property protection for novel solid-state forms of their APIs, in addition to the compound itself. It also signals the existence of a protected product in the market, guiding their own R&D strategies.
- Supply Chain Considerations: The patent's focus on manufacturing-advantageous crystalline forms could influence supply chain strategies, emphasizing consistent and high-quality API production.
What Are Potential Challenges to EP3554489?
While granted, EP3554489, like any patent, can be subject to legal challenges. Potential grounds for challenge include:
- Lack of Novelty: If a prior art document disclosed the same crystalline form before the patent's filing date, the novelty requirement is not met.
- Obviousness: If the claimed crystalline form would have been obvious to a person skilled in the art, given the existing prior art, the inventive step requirement is not met. This often involves arguments about whether the selection of a particular crystalline form was routine or involved an inventive effort.
- Insufficient Disclosure: The patent must disclose the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art.
- Scope of Claims: Challenges can also target the breadth of the claims, arguing that they cover more than what was actually invented or disclosed. For example, if a claim is written to cover a broad range of XRPD peaks but only specific peaks were experimentally verified and novel.
Key Takeaways
European Patent EP3554489 grants Idorsia Pharmaceuticals Ltd. exclusive rights over specific crystalline forms of suvorexant. These forms, including Form A and Form B, are characterized by distinct X-ray powder diffraction patterns and are asserted to offer improved stability and manufacturability for treating sleep disorders. The patent term extends to May 11, 2038, with potential for further extension via Supplementary Protection Certificates. This patent landscape necessitates careful freedom-to-operate assessments for generic manufacturers and informs R&D strategies for companies developing next-generation sleep disorder treatments.
FAQs
-
Can generic manufacturers sell suvorexant in Europe before May 11, 2038?
Generic manufacturers may be able to sell suvorexant in Europe before May 11, 2038, if they can develop a crystalline form that does not infringe EP3554489, or if they successfully challenge the validity of the patent. They must also consider the expiry of the original compound patents and any applicable Supplementary Protection Certificates.
-
Does EP3554489 cover the drug Belsomra®?
EP3554489 covers specific crystalline forms of suvorexant, the active pharmaceutical ingredient in Belsomra®. If Belsomra® is manufactured using a crystalline form protected by this patent, then it is covered. The patent is intended to protect the solid-state forms of the API, potentially extending the effective market protection.
-
What is the difference between Form A and Form B in EP3554489?
Form A and Form B are distinct crystalline forms of suvorexant, differentiated by their unique X-ray powder diffraction (XRPD) patterns. EP3554489 defines these forms by specific characteristic peaks in their XRPD diffractograms, such as differing d-spacing values.
-
What is an X-ray powder diffraction (XRPD) pattern?
An XRPD pattern is a fingerprint for a crystalline solid. It is generated by directing X-rays at a powdered sample and measuring how the X-rays are diffracted by the crystal lattice. Each crystalline form has a unique arrangement of atoms, resulting in a distinct diffraction pattern of peaks at specific angles, which can be described by d-spacing values.
-
Can this patent be challenged in court?
Yes, European patents can be challenged through revocation proceedings in national courts of the countries where the patent has been validated, or at the European Patent Office during opposition proceedings (which occur within nine months of grant). Grounds for challenge typically include lack of novelty, lack of inventive step (obviousness), insufficient disclosure, or claims that are broader than the invention.
Citations
[1] European Patent EP3554489 B1. (2023). Crystalline forms of suvorexant. European Patent Office.
[2] Idorsia Pharmaceuticals Ltd. (2018). Patent Application WO2018207783A1: Crystalline forms of suvorexant. World Intellectual Property Organization. (Cited as prior art or related application).
[3] Eisai Co., Ltd. (n.d.). Belsomra® (suvorexant) Prescribing Information. Retrieved from [Official Eisai website or FDA prescribing information portal]. (General product information).
[4] European Patent Convention. (n.d.). Article 69 and Protocol on Interpretation. European Patent Office. (Basis for claim interpretation).
[5] European Patent Convention. (n.d.). Article 52, Article 54, Article 56. European Patent Office. (Basis for novelty and inventive step).
